
Highmark Health has a program in place, titled Highmark VITAL, that assists in the making of FDA-approved medical technologies available to patients sooner by helping display the efficacy of these therapies. The Pittsburgh organization is a parent company to Highmark BCBS, encompassing the Pennsylvania, Delaware, West Virginia, and Alleghany Health Network.
Through this program, Highmark Health began working with HeartFlow in 2016. This medtech company focuses on using machine learning to develop a 3D heart model, improving diagnosis and treatment of cardiovascular disease. A model such as the one HeartFlow strives to create would allow physicians to better visualize the way a plaque buildup in the heart affects blood flow, and subsequently how to go about treating the patient.
So far, this AI machine learning analysis has been conducted on approximately 100 patients, with results showing that the system can decrease negative angiograms by over 83%, cutting costs by 45% per patient. These profound results were reported by Highmark Health.